Rapport Therapeutics (RAPP) EBITDA (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of EBITDA data on file, last reported at -$20.9 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$20.9 million, up 11.54% year-over-year; the trailing twelve-month figure through Mar 2026 was -$107.7 million (down 35.22% YoY), and the FY2025 annual result was -$110.4 million, down 40.06% from the prior year.
• EBITDA climbed to -$20.9 million in Q1 2026 per RAPP's latest filing, from -$33.4 million in the prior quarter.
• Over five years, EBITDA peaked at -$6.4 million in Q2 2023 and troughed at -$33.4 million in Q4 2025.
• A 4-year average of -$19.9 million and a median of -$20.9 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2026: EBITDA tumbled 183.01% in 2024, then grew 11.54% in 2026.
• A 4-year view of EBITDA shows it stood at -$13.5 million in 2023, then sank by 54.66% to -$20.9 million in 2024, then tumbled by 59.61% to -$33.4 million in 2025, then soared by 37.33% to -$20.9 million in 2026.
• Business Quant data shows RAPP's EBITDA at -$20.9 million in Q1 2026, -$33.4 million in Q4 2025, and -$26.7 million in Q3 2025.